Use this guide one step at a time.
Prostate cancer can range from a small, slow-growing tumor that is monitored to disease that needs combined treatment. Your stage, Grade Group, PSA pattern, imaging, symptoms, health, and priorities belong in the same conversation.
Key points
- If active surveillance is offered, clarify the PSA, examination, MRI, and repeat-biopsy schedule and what finding would trigger treatment.
- Before hormone therapy.
Subtypes and biomarkers
Most prostate cancers are acinar adenocarcinomas, but ductal, neuroendocrine, and other uncommon forms can behave differently and deserve specialist pathology review. For usual adenocarcinoma, the Gleason patterns are combined into Grade Groups 1 through 5; stage and PSA are then used with grade to estimate risk. PSA is useful for monitoring but is not cancer-specific and should be interpreted as a trend and in context. Prostate MRI and prostate-specific membrane antigen imaging can refine the extent of disease in selected settings. Tumor testing in advanced disease can identify DNA-repair alterations, including BRCA1 or BRCA2 changes, that may guide PARP-inhibitor treatment; mismatch-repair deficiency or high microsatellite instability can support immunotherapy in uncommon cases. Germline testing looks for inherited variants and may affect treatment and relatives. Indications can depend on metastatic or high-risk disease, tumor findings, ancestry, and family history, so ask whether genetic counseling is appropriate.
What is prostate cancer?
The prostate is a gland below the bladder that surrounds part of the urethra and contributes fluid to semen. Most prostate cancers arise from gland-forming cells. Their behavior varies widely: some remain confined and unlikely to cause harm, while others invade nearby tissues or metastasize. Age, family history, ancestry, and inherited variants can affect risk, but a risk factor does not determine an individual outcome. PSA is made by prostate tissue and can rise because of cancer, benign enlargement, inflammation, or other causes. Screening decisions require discussion of possible benefits and harms because testing can lead to detection and treatment of indolent disease. Once cancer is found, clinical stage, PSA, Grade Group, imaging, and sometimes genomic or inherited testing are combined into risk groups. These distinctions help determine whether monitoring, local therapy, or systemic treatment is appropriate. Care depends on cancer extent, biology, health, life expectancy, expected side effects, and personal priorities.
Signs and symptoms
Localized prostate cancer often causes no symptoms. Possible urinary changes include a weak or interrupted stream, difficulty starting or stopping urination, frequent urination, urgency, nighttime urination, pain or burning, or blood in urine. Blood in semen, painful ejaculation, or erectile changes can occur. Advanced cancer may cause persistent pain in the back, hips, ribs, or other bones; weakness or numbness in the legs; loss of bladder or bowel control; fatigue; or unexplained weight loss. Benign prostate enlargement, urinary infection, medicines, and other noncancer conditions commonly produce similar urinary symptoms, and PSA elevation is not itself a symptom or diagnosis. New, persistent, or worsening symptoms should be assessed. Sudden leg weakness, numbness, or loss of bladder or bowel control requires urgent evaluation because spinal cord compression is possible.
Diagnosis and staging
Assessment may include history, digital rectal examination, repeat PSA testing, and review of factors that affect PSA. Prostate MRI can identify suspicious areas and help guide biopsy. Diagnosis requires tissue, usually obtained with image-guided needle biopsy. A pathologist assigns a Gleason score and Grade Group, which indicate how abnormal and potentially aggressive the cancer appears. Staging combines examination, PSA, Grade Group, biopsy findings, and selected imaging such as MRI, CT, bone scan, or prostate-specific PET. TNM categories describe the primary tumor, regional lymph nodes, and distant metastases, producing stages I through IV and clinical risk groups. Genomic tumor tests may refine risk in selected localized cases. Inherited-gene testing is important for some people based on metastatic disease, family history, ancestry, or tumor features. Treatment depends on stage, grade, PSA, biomarkers, health, life expectancy, and preferences. Bone symptoms or high-risk features can change which imaging is appropriate.
Established treatment paths
Active surveillance is an established option for many low-risk localized cancers and uses scheduled PSA tests, examinations, imaging, and repeat biopsy to detect meaningful change. Watchful waiting uses less intensive monitoring and focuses on symptoms, often when other health issues limit benefit from curative treatment. Localized disease can also be treated with radical prostatectomy or radiation, including external-beam radiation or brachytherapy. Hormone therapy that lowers or blocks androgens may accompany radiation for higher-risk disease and is central for metastatic cancer. Treatment intensification for metastatic hormone-sensitive disease can include additional androgen-signaling drugs, chemotherapy, or selected combinations. Castration-resistant disease may be treated with other hormonal agents, chemotherapy, targeted drugs such as PARP inhibitors for qualifying genomic alterations, immunotherapy in selected settings, or radiopharmaceuticals. Bone-directed treatments and focused radiation can reduce skeletal complications or pain. Choice requires balancing cancer control against urinary, bowel, sexual, metabolic, cardiovascular, and bone effects. Clinical trials may be appropriate. Care depends on stage, Grade Group, PSA, molecular or inherited findings, symptoms, prior treatment, health, and preferences. Regular monitoring also addresses treatment-related metabolic changes and bone loss.
Supportive care
Supportive planning starts with baseline urinary, bowel, and sexual function. Pelvic-floor rehabilitation may help around prostate surgery, while urinary medicines, continence services, and sexual-health care can address treatment effects. Radiation teams can help manage urinary frequency, bowel irritation, and fatigue. During androgen-deprivation therapy. Metastatic bone disease may require pain treatment, focused radiation, and bone-health measures. Palliative care can support pain, fatigue, sleep, and decision-making alongside active treatment. Fertility concerns and sperm banking should be raised before treatment when relevant. Sudden leg weakness, numbness, or loss of bladder or bowel control needs urgent assessment.
Profiles documenting prostate cancer care
These profiles mention a matching cancer specialty in their published materials. Browse their locations, reported services, and practical details.
Sources
Source information checked: 2026-10-01. The links below identify the public and clinic-provided materials used for this page.
- NCI: Prostate Cancer ↗Checked 2026-09-29
- NCI: Prostate Cancer Treatment ↗Checked 2026-09-29
- NCI: Understanding Prostate Changes ↗Checked 2026-09-29
- NCI: Hormone Therapy for Prostate Cancer ↗Checked 2026-10-01
- NCI PDQ: Genetics of Prostate Cancer ↗Checked 2026-10-01
How Cancer Clinic Finder compiles information · Suggest a factual correction
